[针对埃尔德海姆-切斯特病的分子向治疗]
Makiko Sogabe1, Shogo Murata1, Ken Tanaka1
1Department of Hematology/Oncology, Wakayama Medical University.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|November 5, 2025
概括
埃尔德海姆-切斯特病 (ECD) 治疗通过向治疗显示出有前途. 一种BRAF抑制剂和MEK抑制剂的组合有效地减少了BRAF V600E突变患者的疾病标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学是一种遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃尔德海姆-切斯特病 (ECD) 是一种罕见的非朗格汉斯囊细胞性疾病.
- 目前,对于心电障碍,还没有确定的治疗方法.
- 在一些ECD病例中,BRAF V600E突变与此有关.
研究的目的:
- 报告一个用分子向疗法治疗的ECD病例.
- 评估BRAF抑制剂和MEK抑制剂组合在患有BRAF V600E突变的ECD患者中的疗效和安全性.
主要方法:
- 一名61岁的患有ECD和BRAF V600E突变的女性患者接受了达布拉费尼布 (BRAF抑制剂) 和特拉美丁尼布 (MEK抑制剂) 的联合治疗.
- 治疗包括监测不良事件,包括发烧和肝损伤.
- 用血BRAF V600E等位基因频率和PET/CT扫描来评估反应.
主要成果:
- 患者患有可控的1级发烧和肝损伤,需要暂时停止治疗.
- 治疗成功地恢复了,并添加了普雷迪尼索隆.
- 在8周后,BRAF V600E等位基频率变得无法检测,并且在24周后通过PET/CT确认了部分代谢反应.
结论:
- 分子向疗法,特别是BRAF和MEK抑制剂,证明了对ECD的潜在益处.
- 管理副作用,如发烧和肝损伤,对于成功继续治疗至关重要.
- 需要进行进一步的研究,以建立治疗指南,疗效指标和ECD向治疗的终止标准,因为它很罕见.
更多相关视频
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433


